LYZ and breast carcinoma: Treatment with a preparation containing self-assembled nanostructured lysozyme particles showed a tumor inhibition rate of 31.53 and a survival extension of 4–5 days in different murine tumor models (Das et al., 1992), as well as an inhibition of breast cancer cell migration (Mahanta et al., 2015).